Cencora (NYSE:COR) Updates FY 2024 Earnings Guidance

Cencora (NYSE:COR) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 13.350-13.550 for the period, compared to the consensus earnings per share estimate of 13.440. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on COR. Leerink Partnrs restated an outperform rating on shares of Cencora in a research report on Monday, February 26th. StockNews.com downgraded shares of Cencora from a strong-buy rating to a buy rating in a research report on Thursday, May 2nd. Robert W. Baird boosted their price target on shares of Cencora from $275.00 to $277.00 and gave the stock an outperform rating in a research report on Thursday, May 2nd. Citigroup boosted their price target on shares of Cencora from $265.00 to $280.00 and gave the stock a buy rating in a research report on Tuesday, April 30th. Finally, Mizuho boosted their target price on shares of Cencora from $192.00 to $224.00 and gave the company a neutral rating in a research report on Monday, February 5th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Cencora currently has an average rating of Moderate Buy and a consensus price target of $233.90.

Cencora Trading Down 0.2 %

NYSE:COR opened at $216.75 on Thursday. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. The firm has a market cap of $43.23 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 1.59 and a beta of 0.47. Cencora has a 52 week low of $163.37 and a 52 week high of $246.75. The firm has a 50-day moving average price of $234.60 and a two-hundred day moving average price of $222.17.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The company had revenue of $68.41 billion during the quarter, compared to analyst estimates of $70.60 billion. During the same quarter last year, the business posted $3.50 EPS. Cencora’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities analysts expect that Cencora will post 13.45 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 24th. Investors of record on Friday, May 10th will be issued a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.94%. The ex-dividend date is Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Insider Buying and Selling

In related news, EVP Elizabeth S. Campbell sold 6,977 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $238.12, for a total value of $1,661,363.24. Following the completion of the transaction, the executive vice president now directly owns 8,246 shares of the company’s stock, valued at approximately $1,963,537.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Elizabeth S. Campbell sold 6,977 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $238.12, for a total value of $1,661,363.24. Following the completion of the transaction, the executive vice president now directly owns 8,246 shares of the company’s stock, valued at approximately $1,963,537.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Robert P. Mauch sold 57,564 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the completion of the transaction, the chief operating officer now directly owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 75,295 shares of company stock valued at $17,747,944. Company insiders own 15.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.